Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586643 | 0.83 | KMT2A (0.47) | MAPTKMT2AKAT2BLMNAIDO1 | |
| SCHEMBL17582718 | 0.78 | ALDH1A1 (0.50) | PKMALDH1A1IDO1EDNRA | |
| SCHEMBL17582873 | 0.78 | AKR1B1 (0.50) | PKMALDH1A1MAPTKMT2AMAPK1 | |
| SCHEMBL28073084 | 0.77 | TBXA2R (0.48) | PKMALDH1A1MAPTRAB9AMERTK | |
| SCHEMBL30615492 | 0.76 | MERTK (0.51) | PKMALDH1A1MAPTRAB9AMERTK | |
| SCHEMBL21463469 | 0.76 | MERTK (0.51) | PKMALDH1A1MAPTRAB9AMERTK | |
| SCHEMBL28829832 | 0.76 | MERTK (0.53) | ALDH1A1MAPTRAB9AMERTKVCAM1 | |
| SCHEMBL28073085 | 0.76 | MERTK (0.60) | ALDH1A1MAPTRAB9AMERTKVCAM1 | |
| SCHEMBL429783 | 0.74 | VCAM1 (0.54) | PKMALDH1A1MAPTRAB9AMERTK | |
| SCHEMBL29642899 | 0.73 | MERTK (0.54) | ALDH1A1MAPTRAB9AMERTKVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2018-05-31 | — | — | US | disclosed |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | PKM 313/4885ALDH1A1 2106/4885MAPT 2988/4885 |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | PKM 313/4885ALDH1A1 2106/4885MAPT 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.